Categories: Health

Clariane has successfully completed a bond issue of 400 million euros

Press release
 
June 24, 2025
 

Clariane has successfully completed a bond issue in the amount of 400 million euros

Paris, June 24, 2025 – Clariane (CLARI.PA – ISIN FR0010386334), announces today that it has successfully completed the issuance of an unsecured bond for a total amount of 400 million euros, maturing in 5 years (27 June 2030), contributing to extension of the average maturity of its debt, with an annual coupon of 7.875%.

This bond issue has attracted significant interest from a large number of Tier 1 institutional investors, both French and international. The order book reached an amount in excess of 1.2 billion euros, representing an oversubscription rate of more than 3 times.

With the announcement of the disposal of its Petits-fils home care business on June 12th, Clariane finalized, six months ahead of schedule, its plan to strengthen its financial structure launched on November 14, 2023, for a total amount of €1.5 billion, in order, notably, to restore the Group’s normalized access to financing. This has been achieved with this market issuance, which allows Clariane to extend its maturities and demonstrates the support of investors and its financial partners in its strategy of reducing debt and strengthening its balance sheet.

The net proceeds from this bond issue will be used to refinance its existing debt (including the redemption of its OCEANE).

An application will be made for these bonds to be admitted to trading on the Global Exchange Market of Euronext Dublin. Settlement and admission to trading are expected to take place on 27 June 2025.

This issuance was led by Morgan Stanley as Joint Global Coordinator and Sole Active Bookrunner. Société Générale was the Co-Manager.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, nor a solicitation of an order to purchase or subscribe the notes in any country, in particular in the United States. This press release and the information contained herein also do not constitute an offer to purchase nor a solicitation to sell the notes, nor an invitation to participate to the offer to purchase. The distribution of this press release may be restricted in some countries and be subject to specific regulations and persons in possession of this press release should inform themselves about and comply with any applicable restrictions.

This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, concerning the Group’s future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on 1 April 2025 under registration number D.25-0209, available on the Company’s website (www.clariane.com) and that of the AMF (www.amf-france.org). All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable regulations.

Readers are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane’s past performance should not be taken as a guide to future performance.

The main Alternative Performance Indicators (APIs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the Company’s website at www.clariane.com.

About Clariane

Clariane is the leading European community of care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain.
Relying on their diverse expertise, each year, the Group’s 63,000 professionals provide services to nearly 900,000 patients and residents in three main areas of activity: care homes (Korian, Seniors Residencias, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, etc.), and alternative living solutions (Ages & Vie, etc.).
In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: “taking care of each person’s humanity in times of vulnerability”.

Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September 2024.

Euronext ticker: CLARI.PA – ISIN: FR0010386334.

Stéphane Bisseuil                                                        Benoît Lesieur
       Head of Investor Relations                      Deputy Head of Investor Relations – ESG
        +33 6 58 60 68 69                                                        +33 6 64 80 15 90
                stephane.bisseuil@clariane.com                                benoit.lesieur@clariane.com

        Julie Mary                                                                Florian Bachelet

                                                                             Press officer                                                                      Press officer

        +33 6 59 72 50 69                                                                +33 6 79 86 78 23
                julie.mary@clariane.com                                florian.bachelet@clariane.com

GlobeNews Wire

Recent Posts

Blockchain.com Unveils Highly Anticipated Crypto-Backed Loans, Bringing Borrowing To Crypto Holders Worldwide

The company launches in-house lending for global users starting at 1.9%, delivering one of the…

1 hour ago

Artmarket.com: The Artprice Manifesto: 22 Rules for a Regulated and Transparent Art Market in the Age of AI

Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS, May 14, 2026…

1 hour ago

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

10 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

10 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

10 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

10 hours ago